Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain asibi by deep sequencing

Journal of Infectious Diseases

Volumn 209, Issue 3, 2014, Pages 334-344

  Beck, Andrew ^a,b   Tesh, Robert B ^a,b   Wood, Thomas G ^c   Widen, Steven G ^c   Ryman, Kate D ^d   Barrett, Alan D T ^a,b  

^a Department of Pathology ^*  (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

17D, Viral Population; Deep Sequencing; Flavivirus; Parallel Sequencing; Quasispecies; Vaccine; Variants; Yellow Fever Virus

Indexed keywords

LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE; YELLOW FEVER VIRUS VACCINE;

AMINO ACID SUBSTITUTION; ARTICLE; ASIBI STRAIN; CONTROLLED STUDY; GENE AMPLIFICATION; GENE SEQUENCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; VIRUS GENOME; VIRUS MUTATION; VIRUS STRAIN; WILD TYPE; YELLOW FEVER FLAVIVIRUS;

17D, VIRAL POPULATION; DEEP SEQUENCING; FLAVIVIRUS; PARALLEL SEQUENCING; QUASISPECIES; VACCINE; VARIANTS; YELLOW FEVER VIRUS;

GENOME, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; MUTATION; POLYMORPHISM, GENETIC; RNA, VIRAL; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84892649729     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit546     Document Type: Article

References (43)

1. Neverov A, Chumakov K. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc Natl Acad Sci USA 2010; 107:20063-8.
2. Kennedy RB, Poland GA. The top five "game changers" in vaccinology: toward rational and directed vaccine development. OMICS 2011; 15: 533-7.
3. Luciani F, Bull RA, Lloyd AR. Next generation deep sequencing and vaccine design: today and tomorrow. Trends Biotechnol 2012; 30:443-52.
4. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006; 439:344-8.
5. Holland JJ, De La Torre JC, Steinhauer DA. RNA virus populations as quasispecies. Curr Top Microb Immunol 1992; 176:1-20.
6. Szpara ML, Tafuri YR, Parsons L, et al. A wide extent of inter-strain diversity in virulent and vaccine strains of alphaherpesviruses. PLoS Pathogens 2011; 7:e1002282.
7. Theiler M, Smith HH. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med 1937; 65:767-86.
8. Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010; 84:6033-40.
9. Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007; 52:209-29.
10. Monath TP, Gershman MD, Staples JE, Barrett AD. Yellow fever vaccine. In: Plotkin S, Orenstein W, Offit PA, eds. Vaccines. 6th ed. Philadelphia: Saunders, 2012.
11. Lloyd W, Theiler M, Ricci NI. Modification of the virulence of yellow fever virus by cultivation in tissues in vitro. Trans R Soc Trop Med Hyg 1936; 29:481-529.
12. WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. WHO technical report series. Geneva:World Health Organization, 2010:1-73.
13. Hahn CS, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci USA 1987; 84:2019-23.
14. Dupuy A, Desprès P, Cahour A, Girard M, Bouloy M. Nucleotide sequence comparison of the genome of two 17D-204 yellow fever vaccines. Nucleic Acids Res 1989; 17: 3989.
15. Lee E, Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol 2008; 82:6024-33.
16. Stokes A, Bauer JH, Hudson NP. Experimental transmission of yellow fever to laboratory animals. Am J Trop Med Hyg 1928; 1:103-64.
17. Simpson JT, Wong K, Jackman SD, Schein JE, Jones SJM, Birol I. ABySS: a parallel assembler for short read sequence data. Genome Res 2009; 19:1117-23.
18. Lohse M, Bolger AM, Nagel A, et al. RobiNA: a user-friendly, integrated software solution for RNA-Seq-based transcriptomics. Nucleic Acids Res 2012; 40:W622-7.
19. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9:357-9.
20. Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009; 25:2078-9.
21. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22:568-76.
22. Gentleman R. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer, 2005.
23. Nishijima N, Marusawa H, Ueda Y, et al. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One 2012; 7:e35052.
24. Hunter PR, Gaston MA. Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. J Clin Microbiol 1988; 26:2465-6.
25. Gerstung M, Beisel C, Rechsteiner M, et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun 2012; 3:811.
26. Doran AG, Creevey CJ. Snpdat: easy and rapid annotation of results from de novo snp discovery projects for model and non-model organisms. BMC Bioinformatics 2013; 14: 45.
27. Wang E, Ryman KD, Jennings AD, et al. Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol 1995; 76 (Pt 11):2749-55.
28. Dunster LM, Wang H, Ryman KD, et al. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology 1999; 261:309-18.
29. Xie H, Cass AR, Barrett AD. Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. Virus Res 1998; 55:93-9.
30. Yang Z. Maximum-likelihood estimation of phylogeny from DNA sequences when substitution rates differ over sites. Mol Biol Evol 1993; 10:1396-401.
31. Sil BK, Dunster LM, Ledger TN, Wills MR, Minor PD, Barrett AD. Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus. J Virol 1992; 66: 4265-70.
32. Leung JY, Pijlman GP, Kondratieva N, Hyde J, Mackenzie JM, Khromykh AA. Role of nonstructural protein NS2A in flavivirus assembly. J Virol 2008; 82:4731-41.
33. Bera AK, Kuhn RJ, Smith JL. Functional characterization of cis and trans activity of the Flavivirus NS2B-NS3 protease. J Biol Chem 2007; 282:12883-92.
34. Luo D, Xu T, Watson RP, et al. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J 2008; 27: 3209-19.
35. Muñoz-Jordán JL, Laurent-Rolle M, Ashour J, et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005; 79:8004-13.
36. Zhou Y, Ray D, Zhao Y, et al. Structure and function of flavivirus NS5 methyltransferase. J Virol 2007; 81:3891-903.
37. Zou G, Chen YL, Dong H, et al. Functional analysis of two cavities in flavivirus NS5 polymerase. J Biol Chem 2011; 286:14362-72.
38. Barban V, Girerd Y, Aguirre M, et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007; 25:2941-50.
39. Barrett AD, Monath TP, Cropp CB, et al. Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol 1990; 71(Pt 10):2301-6.
40. Coffey LL, Vasilakis N, Brault AC, Powers AM, Tripet F, Weaver SC. Arbovirus evolution in vivo is constrained by host alternation. Proc Natl Acad Sci USA 2008; 105:6970-5.
41. Ebel GD, Fitzpatrick KA, Lim PY, et al. Nonconsensus West Nile virus genomes arising during mosquito infection suppress pathogenesis and modulate virus fitness in vivo. J Virol 2011; 85:12605-13.
42. Lancaster KZ, Pfeiffer JK. Mechanisms controlling virulence thresholds of mixed viral populations. J Virol 2011; 85:9778-88.
43. Coffey LL, Beeharry Y, Borderia AV, Blanc H, Vignuzzi M. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci USA 2011; 108:16038-43.